Company Achieved New Record-High Monthly and Quarterly Deliveries48,135 vehicles were delivered in December 2025, increasing by 54.6% year-over-year 124,807 vehicles were delivered in the three months ended December 2025, increasing by 71.7% year-over-year 326,028 vehicles were delivered in 2025 in total, increasing by 46.9% year-over-year Cumulative deliveries reached 997,592 as of December 31, 2025  SHANGHAI, Jan. 01, 2026 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its December, fourth quarter and full year 2025 delivery results. The Company delivered 48,135 vehicles in December 2025, a new monthly high, representing an increase of 54.6% year-over-year. The deliveries consisted of 31,897...

BEIJING, China, Jan. 01, 2026 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 44,246 vehicles in December 2025. This brought the Company’s fourth-quarter deliveries to 109,194. As of December 31, 2025, Li Auto’s cumulative deliveries reached 1,540,215. In December 2025, Li Auto surpassed the milestone of 1.5 million cumulative vehicle deliveries. The Company also expanded its global footprint by introducing Li L9, Li L7, and Li L6 to Egypt, Kazakhstan, and Azerbaijan, beginning to establish its market presence across Central Asia, the Caucasus, and Africa. Additionally, the Company officially launched its Li AI glasses, Livis, which received positive user feedback. As of December 31, 2025, the Company had 548...

NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) — Society Pass Incorporated (Nasdaq: SOPA) (the “Company”), Southeast Asia’s (SEA) next generation e-commerce ecosystem, today announced the closing of its previously announced best efforts public offering of an aggregate of 1,500,000 shares of its common stock at a public offering price of $2.00 per share, for aggregate gross proceeds of $3 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The offering was priced at a premium to market under Nasdaq rules. Rodman & Renshaw LLC acted as the exclusive placement agent for the offering. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including operating expenses and capital expenditures. The securities were offered and...

HONG KONG, Dec. 31, 2025 (GLOBE NEWSWIRE) — VS Media Holdings Limited (NASDAQ: VSME, the “Company”), a leader in managing a global network of digital creators, today announced that it plans to implement a 1-for-20 share combination of its Class A ordinary shares (“Class A Ordinary Shares”) and Class B ordinary shares (“Class B Ordinary Shares”) (the “Share Combination”), effective on or around January 9, 2026. Beginning with the opening of trading on January 9, 2026, the Company’s Class A Ordinary Shares will begin trading on a post-Share Combination basis on the Nasdaq Capital Market under the same symbol “VSME”, but under a new CUSIP number of G9517U111. The objective of the Share Combination is to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain...

VANCOUVER, British Columbia, Dec. 31, 2025 (GLOBE NEWSWIRE) — Rio Silver Inc. (“Rio Silver” or the “Company“) is pleased to announce that it has settled an aggregate of $293,250 of indebtedness (the “Debts“) through (1) the issuance of an aggregate of 1,396,428 common shares of the Company at a deemed issuance price of $0.21 per share, of which 976,190 shares were issued to non-arm’s length creditors; and (2) the issuance of an aggregate of 420,238 common share purchase warrants entitling the holders to purchase an aggregate of 420,238 common shares of the Company at a price of $0.28 per share until December 31, 2028, none of which share purchase warrants were issued to non-arm’s length creditors. All common shares and share purchase warrants issued to settle the Debts will be subject...

Salt Lake City, UT, Dec. 31, 2025 (GLOBE NEWSWIRE) — HUMBL, Inc. (OTC: HMBL) today announced that it has initiated a strategic corporate rebrand to TAP Real Estate Technologies, Inc. (“TAP Real Estate”), reflecting the company’s sharpened focus on real estate asset acquisition, ownership, and blockchain-enabled real estate tokenization. In connection with the rebrand, the company will also be submitting an application to change its ticker symbol, subject to regulatory approval. The rebrand marks a formal repositioning of the company toward the next generation of real estate capital formation, where traditional property ownership models converge with digital wallets, blockchain registries, smart contracts, and tokenized investment infrastructure. Initial Capital Raise and Strategic Focus on Blockchain-Enabled Real Estate As part...

MONTREAL, Dec. 31, 2025 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces a first closing of its previously announced non-brokered private placement offering of units of the Company (the “Unit Offering”) for gross proceeds of $450,000. As a result, the Company issued 7,500,015 common shares in the capital of the Company (the “Common Shares”) and 7,500,015 warrants. Each warrant entitles the holder to purchase one Common Share at a price of $0.06 per share for a period of three (3) years from the issuance date. No finders’ fee was paid. The securities underlying the units issued pursuant to the Unit Offering are subject to resale restrictions, including a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws. The Unit Offering...

Clinical Data doubles known genetic factors associated with urate and Gout CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, highlights recent peer-reviewed, independent, published research reports that expand current knowledge that genetic factors are linked to the over-expression of xanthine oxidase (“XO”), high chronic uric acid concentrations in the blood and gout. These ground breaking findings further support the Company’s approach to treating gout, kidney and other diseases by inhibiting XO. Historically, high uric acid concentration in the blood has been associated with increased...